Navigation Links
Robert Sullivan, PhD, Dean of Rady School Of Management, to Join Stemedica Board of Business Advisors
Date:5/2/2013

San Diego, CA (PRWEB) May 02, 2013

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert Sullivan, PhD, dean of the Rady School of Management at the University of California, San Diego (UC San Diego) has agreed to join the Company’s Business Advisory Board. Dr. Sullivan is an expert on entrepreneurship, knowledge management and operations management.

As an Advisor, Dean Sullivan’s specific focus will be Stemedica’s newly formed Cardiology Division which aims to advance Stemedica’s national and international clinical trials in chronic heart failure, acute myocardial infarct and other cardiac conditions. Within this Division, Dr. Sullivan will assist the Company as a liaison between not only the San Diego biotech and business communities, but with organizations worldwide.

As the founding dean of the Rady School of Management, Dr. Sullivan has increased the school’s brand in San Diego and throughout the world. He has successfully recruited top-tier faculty from universities such as the University of Chicago, Massachusetts Institute of Technology (MIT), New York University, Northwestern, Princeton, Stanford, the Wharton School and Yale. In 2011, Dr. Sullivan was elected vice chair-chair elect of the Association to Advance Collegiate Schools of Business (AACSB International), the premier accrediting body for business education.

Dr. Sullivan has held a variety of posts prior to joining the Rady School of Management at UC San Diego. Before coming to San Diego, he was dean of the Kenan-Flagler Business School of The University of North Carolina, Chapel Hill. From 1995 to 1997, he served as director of the University of Texas at Austin’s IC2 Institute, a nontraditional international center for research and education on innovation, creativity, capital and commercialization. Dr. Sullivan served as dean of the Graduate School of Industrial Administration at Carnegie Mellon University from 1991 to 1995. During his tenure, the school’s rankings rose dramatically. He led a reengineering of the school’s educational programs, including integrating advanced technology into the field of finance and creating experiential and international distance-learning opportunities for students. Earlier in his career, he served in a variety of posts at the University of Texas.

Dr. Sullivan holds a doctorate in operations management from Pennsylvania State University, a master’s degree in production management and quantitative methods from Cornell University and a bachelor’s degree in mathematics from Boston College.

Dr. Sullivan commented, “We are fortunate to have such a vibrant biopharmaceutical environment in the San Diego area. Stemedica represents the type of dynamic, emergent company that--with the right blend of strategy, leadership and resources--can become a great success story. The stem cell and regenerative space is growing rapidly and I look forward to contributing my experience and skills to help Stemedica take advantage of this opportunity.”

Maynard Howe, PhD, Chief Executive Officer and Vice Chairman added, “One of the traits of a knowledge-based company is knowing when to reach out to the best external resources to provide a most welcome leadership perspective. We are so very fortunate to have a leading international resource—in the presence of Dean Sullivan—right here in our San Diego community. We look forward to working with him.”

Sergey Sikora, PhD, President of Stemedica’s Cardiology Division added, “We are all very excited about Dean Robert Sullivan joining our Business Advisory Board. It is a true honor to have a business leader of his caliber join our board and assist in the development of our Cardiology Division. He has a track record of bringing business schools from the virtually unknown to world-known premier business education institutions. His experience in rapidly growing organizations will have a huge impact on our organization as well."

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc., contact Dave McGuigan at dmcguigan (at) stemedica.com.

Read the full story at http://www.prweb.com/releases/stemedica-busines-advisor/sullivan-cardiology-rady/prweb10693890.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
2. Robert Farrell Joins Bionovos Board of Directors
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
5. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
6. Robert Haynes To Lead Licensing As VR Laboratories Senior Vice President Product Introduction And Licensing
7. Pittcon Announces 2013 Award Recipients; New Award, Robert Boyle Prize for Analytical Science, Added to Technical Program
8. Robert Storey Joins VIC Technology Venture Development as Executive in Residence
9. Roberto DellOro Named Director of LMUs Bioethics Institute
10. Entertainment Agency and Speaker Bureau Mark Sonder Productions Signs the Health & Wellness Shaman, Robert Cohen, PhD, LPC, DCEP for Meetings and Events Worldwide
11. Dr. J. Robert Beyster and Betty J. Beyster Make $2.5 Million Pledge to the J. Craig Venter Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Allergan plc (NYSE: ... announced that Brent Saunders , Allergan,s CEO and ... a fireside chat session at the RBC Capital Markets ... p.m. ET at The New York Palace Hotel in ... will be webcast live and can be accessed on ...
(Date:2/10/2016)... ... 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will feature ... in San Francisco’s Moscone Center from February 16-18, 2016, and at the healthcare-focused ... latest InGaAs PIN diode standard packages feature a TO-46 metal can with active areas ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... medicine, has announced a new agreement with Singapore-based Global Stem Cells Network (GSCN) ... the Philippines, Thailand and Singapore in the latest adipose and bone marrow therapies. ...
(Date:2/9/2016)... 9, 2016  Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies ... organs, recently reported the Company,s operating results for ... 2016. Lonza America , Inc. (the ... year in the process of consummating an agreement ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):